Hairy and Enhancer of Split-related with YRPW Motif (HEY)2 Regulates Bone Remodeling in Mice*

Received for publication, May 29, 2013 • Published, JBC Papers in Press, June 19, 2013, DOI 10.1074/jbc.M113.489435

Stefano Zanotti†§ and Ernesto Canalis†§†

From the †Department of Research, Saint Francis Hospital and Medical Center, Hartford, Connecticut 06105-1299 and the §University of Connecticut School of Medicine, Farmington, Connecticut 06030

Background: Notch regulates bone mass and induces Hairy and Enhancer of Split-related with YRPW motif (HEY) in osteoblasts, but the contributions of these genes to the skeletal effects of Notch are not fully understood. HEY1 misexpression has limited skeletal impact, female HeyL null mice display increased bone mass, and Hey2 inactivation is developmentally lethal. To inactivate Hey2 in immature or mature osteoblasts, Hey2loxP/loxP mice were crossed with transgenics expressing CRE under the control of the osteirx (Osx-Cre) or osteocalcin (Oc-Cre) promoters to generate Osx-Cre+/−;Hey2Δ/Δ or Oc-Cre+/−;Hey2Δ/Δ mice. Trabecular bone volume increased in 3-month-old Osx-Cre+/−;Hey2Δ/Δ and Oc-Cre+/−;Hey2Δ/Δ male mice and in 1-month-old Oc-Cre+/−;Hey2Δ/Δ female mice, although 3-month-old Oc-Cre+/−;Hey2Δ/Δ females developed osteopenia. Alkaline phosphatase liver/bone/kidney (ALPL) expression and activity were suppressed in osteoblasts from Oc-Cre+/−;Hey2Δ/Δ mice of both sexes. To overexpress HEY2 in osteoblasts, transgenic mice where a 3.6-kb fragment of the rat collagen type-I α1 promoter directs HEY2 expression were created. Three-month-old Hey2 transgenic males exhibited decreased osteoblast activity and increased bone resorption and developed osteopenia at 6 months of age. Hey2 transgenic females exhibited reduced osteoblast number and function, but no changes in bone resorption. HEY2 overexpression in osteoblasts from mice of both sexes inhibited ALPL expression and activity and suppressed osteocalcin transcripts in cells from male mice only. HEY2 overexpression in osteoblasts from male mice enhanced bone resorption by co-cultured splenocytes and induced interleukin-6, a molecule that promotes osteoclastogenesis. In conclusion, HEY2 decreases skeletal mass and regulates bone remodeling in male mice.

Hairy and Enhancer of Split (HES)2-related with YRPW motif (HEY) genes encode 3 helix-loop-helix transcription factors termed HEY1, HEY2, and HEY-Like (HEYL) (1–3). HEY proteins display structural similarities with HES transcription factors and are targets of canonical Notch signaling, a critical regulator of cell differentiation during development and postnatal life (4). HEY proteins play an important role in cardiovascular development. Inactivation of Hey2 results in embryonic lethality due to cardiovascular defects, and the dual inactivation of Hey1 and Hey2 phenocopies the global deletion of Notch1. Similarly, the deletion of Hey1 and HeyL impairs cardiovascular development in mice (5–9).

The continuous renewal of skeletal tissue is carried out in basic multicellular units. There, osteoclasts resorb bone, and following a reversal phase, new bone matrix is deposited by osteoblasts. Osteoblasts are derived from multipotent mesenchymal stem cells that can differentiate toward the osteoblastic, chondrocytic, or adipocytic lineages (10). The commitment of mesenchymal cells to the osteoblastic fate is controlled by a signaling network that includes bone morphogenetic proteins, Wnt, and Notch (11–16). Osteoclasts are multinucleated cells formed by fusion and osteoclastic differentiation of mononuclear cell precursors, a process that requires macrophage-colony stimulating factor (M-CSF) and the receptor activator of nuclear factor-κB ligand (RANKL). RANKL is expressed by osteoclast precursors and is activated following contact with cells expressing the membrane-bound RANKL. The activity of RANKL is opposed by osteoprotegerin (OPG), a soluble RANKL decoy receptor, and the ratio of RANKL over OPG regulates osteoclastogenesis (17, 18).

Notch is a transmembrane receptor activated by direct contact with Notch ligands. In the canonical signaling pathway, the Notch intracellular domain is released following a series of cleavages and forms a complex with Epstein-Barr virus latency

*This work was supported, in whole or in part, by National Institutes of Health Grant DK045227 from the NIDDK (to E. C.) and Research Fellowship Award #11545 from the St. Francis Foundation (to S. Z.).

†To whom correspondence should be addressed: Dept. of Research, Saint Francis Hospital and Medical Center, 114 Woodland St., Hartford, CT 06105-1299. Tel.: 860-714-4068; Fax: 860-714-8053; E-mail: ecanalis@stfranciscare.org.

2The abbreviations used are: HES, Hairy Enhancer of Split; HEY, HES-related with YRPW motif; HeyL, HEY-like; CTX-I, collagen type I C-terminal telopeptide; FVB, tropism to Friend leukemia virus strain-B; pRT, microcomputed tomography; OPG, osteoprotegerin; qRT-PCR, quantitative reverse transcription-PCR; RANKL, receptor activator of NF-κB ligand; Rpl38, ribosomal protein L38; SMI, structure model index.
C promoter binding factor 1, Suppressor of Hairless and Lag-1 (CSL), also termed Rbpjk in mice, and with mastermind-like (MAML). The effects of Notch in the skeleton appear to be mediated by the canonical signaling pathway, but the genes responsible for the biology of Notch in bone have not been defined (19, 20). Hes1, Hes5, Hey1, Hey2, and HeyL are targets of the canonical Notch signaling pathway in skeletal cells, and as such should account, singly or in combination, for the effects of Notch in the skeleton (21). Previously, we reported that HES1 causes osteopenia by inhibiting bone formation and inducing bone resorption in mice (22). These effects of HES1 phenocopied only partially the skeletal phenotype of mice misexpressing Notch in the skeleton, suggesting that HEY proteins may be downstream effectors of Notch signaling in the skeleton (22). Transgenic expression of HEY1 under the control of the ubiquitously expressed β-actin promoter as well as the global inactivation of Hey1 caused mild to modest osteopenia, and global HeyL null mice display increased bone mass (23, 24).

Notch signaling controls osteoclastic differentiation of bone marrow mononuclear precursors and the expression of RANKL and OPG in osteoblastic cells (15, 25, 26). Activation of the Notch signaling pathway in osteoclast precursors regulates osteoclastogenesis, and the cellular context or experimental conditions determine whether Notch suppresses or stimulates osteoclast differentiation (25–29).

In this study, we examined the function of HEY2 in the postnatal skeleton. For this purpose, the skeletal phenotype of mice misexpressing HEY2 was investigated by microcomputed tomography (μCT) and by histomorphometric analysis. To understand the cellular mechanisms involved, the differentiation and function of osteoblasts misexpressing HEY2 were examined in vitro.

**EXPERIMENTAL PROCEDURES**

**Hey2 Conditional Null Mice—**To study the skeletal consequences of Hey2 inactivation in cells of the osteoblastic lineage, mice where the Hey2 sequence comprised between exon 1 and exon 4 was flanked by loxP sites in a 129SV/C57BL/6 background, were provided by E. N. Olson (University of Texas Southwestern Medical Center, Dallas, TX) (6). To express CRE recombinase at early stages of osteoblastic differentiation, we obtained C57BL/6 mice where the CRE coding sequence is cloned downstream of an osteirix (Osx) promoter (Osx-Cre) (The Jackson Laboratory) (30). In these mice, tetracycline suppresses the Osx promoter activity by virtue of a Tet-Off cassette (31). To express CRE preferentially in mature osteoblasts, mice where a 3.9-kb fragment of the human osteocalcin promoter directs CRE expression (Oc-Cre) were obtained from T. Clemens (Johns Hopkins Medicine, Baltimore, MD) and backcrossed for seven generations into a C57BL/6 genetic background. Oc-Cre or Oc-Cre transgensics were crossed with Hey2loxP/loxP mice to create Oc-Cre−/− or Oc-Cre+/− Hey2loxP/loxP mice, which were mated with Hey2loxP/loxP to obtain Oc-Cre+/− or Oc-Cre+/− Hey2loxP/loxP mice. The latter were crossed with Hey2loxP/loxP to generate an experimental cohort, in which CRE excises the loxP-flanked sequences from the Hey2loxP allele (Oc-Cre+/− or Oc-Cre+/−;Hey2loxP) and littermate controls (Hey2loxP/loxP). To prevent Oc-Cre expression during embryonic development, pregnant mothers were administered chow containing 625 mg/kg of doxycycline (Harlan Laboratories, Indianapolis, IN) from the time of conception to delivery. The presence of the Osx-Cre and Oc-Cre transgenes and of the Hey2loxP allele was determined by PCR in tail DNA extracts in newborns and adult mice, and primers specific for fatty acid-binding protein 1 (Fabp1) were used as positive controls in the PCR reactions. Recombination of sequences flanked by loxP sites was assessed by PCR in DNA extracts from parietal bone, using primers specific for the Hey2loxP allele. All animal experiments were approved by the Animal Care and Use Committee of Saint Francis Hospital and Medical Center.

**Col3.6-Hey2 Transgenic Mice—**For preferential expression of HEY2 in osteoblasts, a 1047-bp DNA fragment coding for murine HEY2 (American Type Culture Collection; ATCC, Manassas, VA), preceded by a Kozak consensus sequence, was cloned downstream of a 3.6-kb fragment of the rat Col1a1 (collagen type I α1) promoter and upstream of the bovine growth hormone polyadenylation signal (32). Microinjection of linearized DNA into pronuclei of fertilized oocytes from Friend leukemia virus strain B (FVB) mice (Charles River Laboratories, Wilmington, MA) and transfer of microinjected embryos into pseudopregnant mice were carried out at the Gene Targeting and Transgenic Facility of the University of Connecticut Health Center (Farmington, CT). Positive founders were identified by Southern blot analysis of tail DNA and bred to wild type FVB mice to create Col3.6-Hey2 transgenic lines (33). To assess the effects of HEY2 overexpression, heterozygous Col3.6-Hey2 mice were mated to wild type FVB mice to generate heterozygous Col3.6-Hey2 transgenic mice and wild type littermate controls. The presence of the Col3.6-Hey2 transgene was documented by PCR in tail DNA. To assess mRNA expression in skeletal cells, calvariae were frozen in liquid nitrogen at the time of harvest and transferred to −80 °C for storage before RNA extraction. To determine levels of bone resorption, fasting serum concentration of collagen type 1 C-terminal telopeptide (CTX-I), was measured by using the RatLaps enzyme-linked immunosorbent assay in accordance with the manufacturer’s instructions (Immuno Diagnostic Systems, Scottsdale, AZ) (34).

**Microcomputed Tomography—**Femurs were scanned in 70% ethanol at an energy level of 55 kVp, an intensity of 145 μA, and an integration time of 200 ms on a μCT 40 scanner (Scanco Medical AG, Bassersdorf, Switzerland). Trabecular bone volume fraction and microarchitecture were evaluated starting ~1.0 mm proximal to the femoral condyles. A total of 160 consecutive slices acquired at an isotropic voxel size of 216 μm3 and a slice thickness of 6 μm were chosen for analysis. Contours were manually drawn every 10 slices a few voxels away from the endocortical boundary to define the region of interest for analysis. The contours of the remaining slices were iterated automatically. Trabecular regions were assessed for bone volume fraction, trabecular thickness, number and separation, connectivity density, and structure model index (SMI), using a Gaussian filter (σ = 0.8) and a user-defined threshold (35). A total of 100 slices for the cortical region were measured at the mid-diaphysis of each femur with an isotropic voxel size of 216 μm3 and a slice thickness of 6 μm. For mid-diaphysis analysis, con-
tours were iterated across the 100 slices along the cortical shell, excluding the bone marrow cavity. Analysis for cortical thickness was performed using a Gaussian filter ($\sigma = 0.8$) and a user-defined threshold (35).

*Bone Histomorphometric Analysis*—Static and dynamic histomorphometry of femurs was carried out after injection with 20 mg/kg calcein and 50 mg/kg demeclocycline, at an interval of 2 days for 1-month-old mice and 7 days for 3- and 6-month-old mice. Animals were sacrificed by CO$_2$ inhalation 2 days after the demeclocycline injection. Femurs were sectioned on a microtome at a thickness of 5 μm (Microm, Richards-Allan Scientific, Kalamazoo, MI) and stained with 0.1% toluidine blue. Static parameters of bone formation and resorption were measured in a defined area between 360 and 2160 μm from the growth plate, using an OsteoMeasure morphometry system (Osteometrics, Atlanta, GA) (36). For dynamic histomorphometry, mineralizing surface per bone surface and mineral apposition rate were measured on unstained sections under ultraviolet light, using a triple diamino-2-phenylindole fluorescein set long pass filter, and bone formation rate was calculated. The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral Research (37).

*Osteoblast Cultures*—Osteoblast-enriched cultures were isolated from parietal bones of 3–5-day-old male or female Oc-Cre$^{+/-}$;Hey2$^{2A+/A}$ or Col3.6-Hey2 transgenic mice and littersmate controls of the same sex by sequential collagenase digestion, as described (38). The sex of newborn mice was determined by PCR analysis of tail DNA with 5'-GAGAGCA-TGGAGGGCAT-3' forward and 5'-GAGTACAGGTGTGCA-GCTC-3' reverse primers amplifying a 400-bp fragment of sex-determining region Y, located on chromosome Y, and with 5'-TGGACAGGACTGACCTCAGTTCC-3' forward and 5'-TAGAGGTTGCAACATCAGGTCAT-3' reverse primers amplifying a 200-bp fragment of the autosomal gene fatty acid-binding protein 1. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM, Life Technologies) supplemented with 10% fetal bovine serum (FBS; Atlanta Biologicals, Norcross, GA) at 37°C in a humidified 5% CO$_2$ incubator.

*Quantitative Reverse Transcription-PCR* (qRT-PCR)—Total RNA was extracted from cells with the RNeasy mini kit, according to the manufacturer’s instructions (Qiagen, Valencia, CA), and from frozen calvariae by phenol/chloroform extraction (Sigma-Aldrich), and changes in mRNA levels were determined by qRT-PCR. 0.5–1 μg of total RNA was reverse-transcribed using the iScript cDNA synthesis kit (Bio-Rad Laboratories) and from frozen calvariae by phenol/chloroform extraction (Qiagen, Valencia, CA), and amplified in the presence of 5'-TGTTATGGGCGCTTCTCACA-GTAAACC-3' forward and 5'-CTTGGAGAGGGCCACAAAGG-3' reverse primers for alkaline phosphatase liver/bone/ kidney (Alpl; NM_007431), 5'-CCCCCTCTGGAAGAGGTG-GCGCT-3' forward and 5'-AGCTCCCCTCTCAGCTC-TGG-3' reverse primers for osteocalcin (Opg; NM_001048057, NM_001048058, and NM_023372) and iQ SYBR Green supermix (Bio-Rad Laboratories) at 60°C for 45 cycles, according to the manufacturer's instructions. Transcript copy number was estimated by comparison with a dilution series of Alpl and Rpl38 (both from ATCC), Gapdh (R. Wu, Cornell University, Ithaca, NY), Hey2 (T. Iso, University of Southern California, Los Angeles, CA), Il6 and Opg (both from Open Biosystems, Huntsville, AL), osteocalcin (J. B. Lian, University of Massachusetts, Worcester, MA), and Rankl (Source BioScience, Nottingham, UK) cDNA (39–43). Reactions were conducted in a CFX96 qRT-PCR detection system (Bio-Rad Laboratories), and fluorescence was monitored at the annealing step of every PCR cycle. Specificity of the reaction was confirmed by the presence of a single peak in the melt curve analysis of PCR products.

*Alkaline Phosphatase Activity*—Alkaline phosphatase activity was determined in cell extracts by the hydrolysis of p-nitrophenyl phosphate to p-nitrophenol, measured by spectroscopy at 405 nm according to manufacturer’s instructions (Sigma-Aldrich). Data are expressed as nanomoles of p-nitrophenol released per minute per μg of protein measured by the DC protein assay (Bio-Rad Laboratories).

*Osteoblast-Splenocyte Co-Cultures and Pit Formation Assay*—Primary osteoblasts from male Col3.6-Hey2 transgenic mice and male littermate controls were seeded on BioCoat discs (BD Biosciences), and after reaching confluence, cultured in the presence of 100 μg/ml ascorbic acid and 5 mM β-glycerophosphate. Primary splenocytes were harvested from spleens aseptically removed from 1-month-old wild type FVB male mice, and $1 \times 10^6$ cells/cm$^2$ were seeded on the layer of primary osteoblasts in the presence of 10 nM 1,25 dihydroxyvitamin D$_3$ (BioMol International, Plymouth Meeting, PA) or phosphate-buffered saline, as control (44–46). Splenocytes and primary osteoblasts were cultured for 7 days, cells were removed with bleach for 5 min, and BioCoat discs were stained with von Kossa. Stained discs were photographed on a white light background and a digital grayscale image analyzed with Adobe Photoshop (Adobe Systems, Inc., San Jose, CA). The negative image was obtained with the invert feature of Adobe Photoshop, brightness and contrast were maximized, and the area of resorption was calculated as the percentage of pixels contained in half of the grayscale, determined by using the histogram function of Adobe Photoshop (22).

*Statistical Analysis*—Data are expressed as means ± S.E. Statistical differences were determined by Student’s $t$ test or anal-
Hey2 Inactivation in Cells of the Osteoblastic Lineage Causes a Transient Increase in Bone Volume—To investigate the function of Hey2 at early stages of osteoblast maturation and in differentiated osteoblasts, the skeletal phenotype of Osx-Cre^{+/−};Hey2^{Δ/Δ} or Oc-Cre^{+/−};Hey2^{Δ/Δ} mice was compared with the phenotype of littermate Hey2^{loxP/loxP} controls of the same sex. Recombination of Hey2 sequences flanked by loxP sites was detected in DNA extracts from calvariae of 1- and 3-month-old Osx-Cre^{+/−};Hey2^{Δ/Δ} and Oc-Cre^{+/−};Hey2^{Δ/Δ} mice, whereas recombination was not observed in littermate controls (Fig. 1, A and B, and data not shown). Osx-Cre^{+/−};Hey2^{Δ/Δ} and Oc-Cre^{+/−};Hey2^{Δ/Δ} mice were viable, appeared normal, and did not exhibit differences in mortality when compared with littermate controls.

In initial experiments, we demonstrated that Oc-Cre, Osx-Cre, and Hey2^{loxP/loxP} did not exhibit an appreciable skeletal phenotype as determined by μCT at 1 month of age (48). One-month-old Osx-Cre^{+/−};Hey2^{Δ/Δ} male mice did not display a skeletal phenotype. μCT analysis of femurs from 3-month-old Osx-Cre^{+/−};Hey2^{Δ/Δ} male mice revealed increased trabecular bone volume and connectivity, secondary to increased trabecular number (Table 1, Fig. 1C). However, no changes in parameters of bone formation or bone resorption were observed by histomorphometric analysis (data not shown). No skeletal phenotype was observed in Osx-Cre^{+/−};Hey2^{Δ/Δ} female mice by μCT analysis (Table 1, Fig. 1C), indicating that Hey2 inactivation at early stages of osteoblast differentiation increases bone mass only in male mice.

Oc-Cre^{+/−};Hey2^{Δ/Δ} male mice at 1 month of age did not exhibit changes in trabecular bone volume, although these mice displayed a limited reduction in mineral apposition rate and bone formation rate (Fig. 1D, Table 2). Three-month-old Oc-Cre^{+/−};Hey2^{Δ/Δ} male mice developed increased bone volume/tissue volume, indicating that the suppressed osteoblast function at 1 month of age does not translate into osteopenia in older mice (Table 2, Fig. 1D). In addition, inactivation of Hey2 in 3-month-old male mice resulted in lower SMI (Table 2, Fig. 1E).
Hey2 Inactivation Impairs Osteoblast Function in Vitro—To explore the cellular mechanisms that lead to suppressed bone formation, we investigated the effects of Hey2 inactivation on osteoblast function. Using primary osteoblast cultures from Hey2+/- mice, we found that Hey2 inactivation resulted in a significant reduction in osteoblast proliferation, osteocalcin expression, and osteocalcin secretion compared to control cells. These findings are consistent with previous studies demonstrating the role of Hey2 in maintaining osteoblast viability and function. However, further investigation is necessary to elucidate the specific mechanisms underlying Hey2-dependent osteoblast dysfunction.
form in Oc-Cre+/--; Hey2Δ/Δ mice, primary osteoblastic cells were harvested from Oc-Cre+/--; Hey2Δ/Δ male or female mice and littermate Hey2loxP/loxP controls of the same sex. Alkaline phosphatase transcripts and activity were decreased in the context of Hey2 inactivation in primary calvarial osteoblasts from mice of both sexes (Fig. 2). These findings are in agreement with the decrease in mineral apposition rate exhibited by Hey2 null mice and indicate that HEY2 is required for full osteoblastic function.

**FIGURE 2. Hey2 inactivation inhibits osteoblast function in vitro.** Osteoblast-enriched cells were harvested from calvariae of male or female Oc-Cre+/--; Hey2Δ/Δ mice (Hey2 null, black bars), or littermate Hey2loxP/loxP controls of the same sex (Control, white bars) and cultured under conditions favoring osteoblastogenesis. Total RNA was extracted, and mRNA was reverse-transcribed and amplified by qRT-PCR in the presence of specific primers. Data are expressed as Alpl copy number, corrected for Rpl38 copy number. Values are means ± S.E., n = 3–4. Alkaline phosphatase activity was determined in cells extracted with Triton X-100, and data are expressed as nanomoles of p-nitrophenol/min/µg of total protein. Values are means ± S.E., n = 6, +, significantly different between day 7 and day 0, p < 0.05, * significantly different between HEY2 and control, p < 0.05.

**TABLE 3**

Microcomputed tomography (µCT) and histomorphometry of the femur of 1, 3 and 6 month old Col3.6-Hey2 transgenic male mice (HEY2), or littermate wild type controls of the same sex

| 1 month | 3 month | 6 month |
|---------|---------|---------|
| **µCT (males)** | | |
| Bone volume (% | Wild type | HEY2 | Wild type | HEY2 | Wild type | HEY2 | Wild type | HEY2 |
| Bone trabecular separation (µm) | 212 ± 11 | 204 ± 11 | 270 ± 10 | 259 ± 5 | 366 ± 3 | 356 ± 16 | 278 ± 0.1 | 284 ± 0.12 |
| Bone trabecular number (mm⁻¹) | 4.80 ± 0.04 | 5.93 ± 0.29 | 3.77 ± 0.13 | 3.91 ± 0.07 | 38.2 ± 1.5 | 34.7 ± 2.1 | 83.0 ± 0.8 | 84.0 ± 0.7 |
| Bone trabecular thickness (µm) | 24.7 ± 0.7 | 26.3 ± 0.3 | 29.8 ± 1.2 | 29.7 ± 0.9 | 138 ± 15 | 140 ± 15 | 103 ± 11 | 48 ± 10 |
| Bone connectivity density (mm⁻³) | 2.35 ± 0.02 | 3.38 ± 0.44 | 2.66 ± 0.13 | 2.75 ± 0.06 | 2.03 ± 0.15 | 2.74 ± 0.14 | |
| Bone structure model index (SMI) | 2.85 ± 0.11 | 2.52 ± 0.06 | 182 ± 4 | 177 ± 1 | 192 ± 3 | 189 ± 3 | |
| Bone cortical thickness (µm) | 119 ± 2 | 117 ± 3 | 182 ± 4 | 177 ± 1 | 192 ± 3 | 189 ± 3 | |

| **Histomorphometry (males)** | | |
| Bone volume/tissue volume (%) | 8.8 ± 0.4 | 9.9 ± 1.8 | 6.5 ± 0.6 | 7.6 ± 0.3 | 4.8 ± 0.9 | 3.5 ± 0.4 |
| Bone trabecular surface/area (%) | 17.0 ± 1.8 | 15.6 ± 2.2 | 12.7 ± 1.5 | 10.9 ± 1.1 | 11.1 ± 1.0 | 14.5 ± 1.4 |
| Bone trabecular bone surface (%) | 17.2 ± 1.8 | 15.3 ± 2.4 | 15.5 ± 1.8 | 12.8 ± 1.4 | 11.4 ± 1.1 | 15.4 ± 2.4 |
| Bone trabecular bone surface (%) | 1.0 ± 0.2 | 1.4 ± 0.3 | 0.9 ± 0.1 | 0.7 ± 0.2 | 0.8 ± 0.4 | 0.5 ± 0.2 |
| Bone trabecular bone surface (%) | 11.3 ± 0.7 | 10.6 ± 0.6 | 9.3 ± 0.5 | 10.9 ± 0.6 | 8.1 ± 0.4 | 8.3 ± 0.7 |
| Bone trabecular bone surface (%) | 7.3 ± 0.4 | 7.1 ± 0.3 | 6.0 ± 0.3 | 7.2 ± 0.4 | 5.7 ± 0.3 | 5.8 ± 0.6 |
| Bone trabecular bone surface (%) | 23.1 ± 1.1 | 22.2 ± 1.5 | 13.8 ± 0.7 | 17.9 ± 1.0 | 13.8 ± 0.7 | 13.6 ± 1.1 |
| Bone mineral apposition rate (µm day⁻¹) | 2.53 ± 0.20 | 3.33 ± 0.17 | 0.60 ± 0.04 | 0.53 ± 0.03 | 0.49 ± 0.03 | 0.46 ± 0.04 |
| Bone mineralization surface/bone surface (%) | 3.0 ± 0.3 | 3.3 ± 0.5 | 10.9 ± 1.0 | 6.5 ± 1.0 | 5.5 ± 1.2 | 8.2 ± 2.0 |
| Bone formation rate (µm² µm⁻³ day⁻¹) | 0.08 ± 0.01 | 0.08 ± 0.02 | 0.07 ± 0.01 | 0.04 ± 0.01 | 0.03 ± 0.01 | 0.04 ± 0.01 |

**HEY2 Overexpression in Osteoblasts Uncouples Bone Formation from Bone Resorption—**To test further the function of HEY2 in the skeleton, the effects of the preferential HEY2 overexpression in osteoblasts were investigated in Col3.6-Hey2 transgenic mice at 1, 3, and 6 months of age. Three transgenic founders were obtained, and only one male founder mouse transmitted the transgene to the offspring, allowing the establishment of a Hey2 transgenic line. Col3.6-Hey2 transgenics were born at the expected Mendelian ratio and appeared normal and healthy. qRT-PCR analysis demonstrated that Hey2 mRNA levels, corrected for Rpl38 expression, in calvariae from 1-month-old Col3.6-Hey2 transgenic males and females mice were increased 32.9 ± 3.4- and 32.2 ± 10.6-fold (p < 0.05), respectively, in comparison with control littermates of the same sex, confirming expression of the Col3.6-Hey2 transgene.

µCT revealed that Col3.6-Hey2 male transgenics did not exhibit a phenotype at 1 or 3 months of age, but were osteopenic at 6 months of age. The SMI value closer to 3 in the Col3.6-Hey2 transgenic male mice indicated a preponderance of rod-like over plate-like trabeculae, suggesting that HEY2 affects bone microarchitecture (Table 3, Fig. 3) (49). Histomorphometric analysis revealed that Col3.6-Hey2 transgenics had increased osteoclast number and eroded surface and decreased bone formation rate at 3 months of age (Table 3). However, HEY2 overexpression did not affect serum levels of CTX-I, a marker of bone resorption, in 1-month-old male mice (data not shown) (34). The changes in the cellular parameters observed at 3 months of age may explain the reduced bone volume observed in 6-month-old male mice, suggesting that overexpression of HEY2 in osteoblasts causes osteopenia due to an uncoupling of osteoblast and osteoclast activities.

µCT and histomorphometric analysis indicated that Col3.6-Hey2 transgenic female mice did not exhibit an obvious skeletal phenotype at 1, 3, and 6 months of age, except for a decrease in bone formation rate at 6 months of age (Table 4, Fig. 3). No changes in osteoclast number, eroded surface, or serum levels of CTX-I were observed, indicating that HEY2 overexpression...
in osteoblasts regulates osteoclast differentiation and function only in male mice.

**HEY2 Overexpression Impairs Osteoblast Function in Vitro**—To understand the cellular effects caused by HEY2 overexpression, osteoblast-enriched cells were harvested from calvariae of Hey2 transgenic male or female mice and littermate controls of the same sex. Increased HEY2 transcripts were confirmed by qRT-PCR in osteoblasts from Col3.6-Hey2 transgenic male but not female transgenic mice (Fig. 4). Alkaline phosphatase transcripts and activity were suppressed by HEY2 in cells from both sexes and activity were suppressed by HEY2 in cells from both sexes and function in both sexes and could explain the decreased bone formation and osteoblast number observed in vivo.

**HEY2 Overexpression Enhances Osteoclast Function in Vitro**—To determine whether the overexpression of HEY2 regulated osteoclast differentiation or function, calvariae from male Col3.6-Hey2 transgenics and littermate wild type controls were co-cultured with wild type FVB splenocytes, a source of mononuclear osteoclast precursors. Treatment with 1,25-dihydroxyvitamin D3 induced resorptive activity of wild type splenocytes, and in agreement with the increased eroded surface and osteoclast number observed in the Col3.6-Hey2 transgenic males, osteoblasts from Col3.6-Hey2 transgensics enhanced resorption (Fig. 5A) (44). To investigate possible mechanisms for the stimulatory effect of HEY2 on bone resorption, interleukin-6 (IL6) Rankl and Opg mRNA levels were determined (50). An increase in IL6 transcripts was observed only in male Col3.6-Hey2 transgenic osteoblasts (Fig. 5B), suggesting that HEY2 increases bone resorption by inducing the expression of IL6. HEY2 caused a modest and unexplained increase in Rankl transcripts in osteoblasts from female mice. In accordance with the effects of Notch on OPG expression, HEY2 induced Opg mRNA levels in cells from male mice (Fig. 5B) (26, 48). This may represent an indirect compensatory mechanism to temper the effects of HEY2 on osteoclastogenesis.

**DISCUSSION**

In this study, we investigated the skeletal function of Hey2, a Notch target gene. Hey2 inactivation in cells of the osteoblastic lineage caused an increase in trabecular bone volume, an effect
that is consistent with the osteopenic phenotype caused by the activation of Notch signaling in these cells (16, 48). The skeletal phenotype was mild, transient, and more pronounced in male than in female mice, indicating that Hey2 plays a modest role in skeletal homeostasis. Inactivation of Hey2 at early stages of osteoblastic differentiation did not affect the number or function of skeletal cells, and a developmental nature for the increased bone mass is excluded because the activity of the Osx promoter was suppressed by doxycycline during embryonic development (30). Global HeyL null mice carrying a heterozygous null mutation of Hey1 exhibit increased bone mass, indicating that Hey1, HeyL, and Hey2 have similar functions in the skeleton (24). It is plausible that Hey1 and HeyL compensate for the loss of Hey2 function, preventing detection of subtle changes in osteoblast and osteoclast number and activity, which lead to a modest increase in bone mass. Compensation by Hey1 might explain the sexually dimorphic skeletal phenotype of Hey2 inactivation in immature osteoblastic cells because Hey1 transcript levels significantly increased 1.4-fold in parietal bones when Hey2 was inactivated in female mice, but not in
male mice (data not shown). Inactivation of Hey2 in osteoblasts did not affect serum markers of bone remodeling and transiently inhibited bone formation, but the effect was modest, confirming that Hey2 has a limited impact on skeletal function.

Although three Hey2 transgenic founders were obtained, only one transgenic line was established, indicating that excessive levels of Hey2 in cells expressing the 3.6-kb fragment of the Col1a1 promoter are detrimental for embryonic development. The activity of this promoter fragment is not restricted to osteoblastic cells, and expression of Hey2 in nonskeletal tissues may have prevented transmission of the transgene (51, 52). Despite these limitations, the data indicate that Hey2 overexpression affects bone remodeling and uncouples bone formation from bone resorption by increasing osteoclastogenesis in male mice and by suppressing osteoblast number and function in both genders. In accordance with the effects of the Hey2 inactivation in osteoblastic cells, Col3.6-Hey2 transgenic male mice displayed osteopenia and impaired trabecular microarchitecture at 6 months of age. However, the inhibition of osteoblast number and activity in female mice did not result in changes in trabecular volume or structure. There is no immediate explanation for the discrepancy in the skeletal phenotype of male and female transgensics, and it is conceivable that mechanisms necessary for the protection of bone mass are at play in female mice in the context of Hey2 overexpression. Alternatively, a variable penetrance of the Col3.6-Hey2 transgene may be responsible for the absence of changes in trabecular bone of female transgensics.

The differences between the skeletal phenotypes observed in the two sexes also could be explained by a sexually dimorphic mechanism of Hey2 action in osteoblasts. Hey2 is a paralogue of Hes1, and Hes1 overexpression under the control of the 3.6-kb fragment of the Col1a1 promoter induces osteoclastogenesis in male mice and suppresses osteoclastogenesis in female mice, confirming that the skeletal effects of the HES and Hey families of proteins are sexually dimorphic (22). An explanation for the sexual dimorphism could be provided by the protective effects of estrogens on skeletal mass (53).

In vitro studies exploring the differentiation and function of osteoblastic cells from mice misexpressing Hey2 indicate that Hey2 is dispensable for osteoclastogenesis and that perturbation of its expression in mature cells suppresses osteoblast function in both male and female mice. Although the mechanism was not established, it is possible that Hey2, like Hey1, interacts with transcription factors necessary for osteoclastogenesis, such as Runx2 (15). The decreased osteoblastic function by Hey2 inactivation is not consistent with the effects of Notch on mature cells of the osteoblastic lineage. The suppressive effects of Hey2 on transcription might explain this discrepancy because the absence of Hey2 might lead to increased expression of inhibitors of osteoblastic function (1, 3). Results from cells overexpressing Hey2 are in agreement with the inhibitory effects of Notch overexpression on osteoblast function (4). Overexpression of Hey2 in osteoblasts causes a less severe skeletal phenotype than the one observed following the induction of Notch under the control of the 3.6-kb fragment of the Col1a1 promoter. This may suggest that the skeletal effects of Notch require expression of additional targets of Notch signaling, such as HES1, or are primarily mediated by direct regulation of osteoblast-specific genes by Notch (16).

The increased bone resorption reported in Hey2 transgenic mice does not phenocopy the inhibitory effect of Notch on osteoclastogenesis, which is mediated by an induction of OPG and suppression of RANKL and M-CSF expression by osteoblastic cells (15, 25, 26, 48). HES1 is an inducer of osteoclastogenesis, suggesting that HEY and HES transcription factors carry out functions that are independent from their role as targets of Notch signaling (22). We report an induction of Il6 expression by Hey2 in osteoblasts from male mice, suggesting a possible mechanism for the enhanced bone resorption observed in male Col3.6-Hey2 transgenics. However, Hey2, like Notch, induced OPG expression, and this may be a protective mechanism to prevent excessive osteoclastogenesis. IL6 serum levels were not increased in Col3.6-Hey2 transgenic mice (data not shown), indicating that IL6 acts locally to regulate bone resorption. Although IL6 regulates osteoclastogenesis by inducing RANKL in osteoblastic cells, its direct effects on cells of the osteoclast lineage are less clear, and both a stimulatory function and an inhibitory function of IL6 in the differentiation of osteoclast precursors have been reported (54, 55). Our observations indicate that in the context of HEY2 overexpression, IL6 promotes the resorptive activity of osteoclast precursors.

In conclusion, Hey2 plays a modest role in the regulation of skeletal cell function, whereas HEY2 overexpression in male mice uncouples bone formation from bone resorption, causes osteopenia, and compromises bone microarchitecture.

Acknowledgments—We thank Drs. E. Olson for Hey2loxP/loxP conditional mice, T. Clemens for osteocalcin-CRE transgenics, J. B. Lian for osteocalcin, and R. Wu for GAPDH cDNA. We thank A. Kent, K. Parker, and L. Kranz for technical support and M. Yurczak for secretarial assistance.

REFERENCES
1. Iso, T., Kedes, L., and Hamamori, Y. (2003) HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell Physiol. 194, 237–255
2. Kageyama, R., Ohtsuka, T., and Kobayashi, T. (2007) The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development 134, 1243–1251
3. Fischer, A., and Gessler, M. (2007) Delta–Notch—and then? Protein interactions and proposed modes of repression by Hes and Hey bHLH factors. Nucleic Acids Res. 35, 4583–4596
4. Zanotti, S., and Canalis, E. (2010) Notch and the skeleton. Mol. Cell Biol. 30, 886–896
5. Kokubo, H., Miyagawa-Tomita, S., Tomimatsu, H., Nakashima, Y., Nakazawa, M., Saga, Y., and Johnson, R. L. (2004) Targeted disruption of hesr2 results in atrioventricular valve anomalies that lead to heart dysfunction. Circ. Res. 95, 540–547
6. Xin, M., Small, E. M., van Rooij, E., Qi, X., Richardson, J. A., Srivastava, D., Nakagawa, O., and Olson, E. N. (2007) Essential roles of the bHLH transcription factor Hr2 in repression of atrial gene expression and maintenance of postnatal cardiac function. Proc. Natl. Acad. Sci. U.S.A. 104, 7975–7980
7. Fischer, A., Steidl, C., Wagner, T. U., Lang, E., Jakob, P. M., Friedl, P., Knoebeloch, K. P., and Gessler, M. (2007) Combined loss of Hey1 and HeyL causes congenital heart defects because of impaired epithelial to mesenchymal transition. Circ. Res. 100, 856–863
HEY2 and Bone Remodeling

8. Fischer, A., Schumacher, N., Maier, M., Sendtner, M., and Gessler, M. (2004) The Notch target genes Hey1 and Hey2 are required for embryonic vascular development. *Genes Dev.* 18, 901–911

9. Kokubo, H., Miyagawa-Tomita, S., Nakazawa, M., Saga, Y., and Johnson, R. L. (2005) Mouse *hes1* and *hes2* genes are redundantly required to mediate Notch signaling in the developing cardiovascular system. *Dev. Biol.* 278, 301–309

10. Bianco, P., and Gehron Robey, P. (2000) Marrow stromal stem cells. *J. Clin. Invest.* 105, 1663–1668

11. Canalis, E., Giustina, A., and Bilezikian, J. P. (2007) Mechanisms of anabolic therapies for osteoporosis. *N. Engl. J. Med.* 357, 905–916

12. Canalis, E., Economides, A. N., and Gazzarino, E. (2003) Bone morphogenic proteins, their antagonists, and the skeleton. *Endocr. Rev.* 24, 218–235

13. Westendorf, J. J., Kahler, R. A., and Schroeder, T. M. (2004) Wnt signaling in osteoblasts and bone diseases. *Gene* 314, 19–39

14. Engin, F., Yao, Z., Yang, T., Zhou, G., Bertin, T., Jiang, M. M., Chen, Y., Wang, L., Zheng, H., Sutton, R. E., Boyce, B. F., and Lee, B. (2008) Dimorphic effects of Notch signaling in bone homeostasis. *Nat. Med.* 14, 299–305

15. Hilton, M. J., Tu, X., Wu, X., Bai, S., Zhao, H., Kobayashi, T., Kronenberg, H. M., Teitelbaum, S. L., Ross, F. P., Kopan, R., and Long, F. (2008) Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. *Nat. Med.* 14, 306–314

16. Zanotti, S., Smerdel-Ramoya, A., Stadmeyer, L., Durant, D., Radtke, F., and Canalis, E. (2011) Reciprocal regulation of Notch and nuclear factor of activated T-cells (NFAT) c1 transcription factor leads to osteopenia and chondrodysplasia. *Endocrinology* 152, 192–205

17. Lacey, D. L., Timms, E., Tan, H. L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombo, A., Elliott, G., Scully, S., Hsu, H., Sullivan, J., Hawkins, N., Davy, E., Capparelli, C., Eli, A., Qian, Y. X., Kaufman, S., Surendran, K., Kopan, R., Gessler, M., and Long, F. (2012) Physiological regulation of vitamin D-dependent expression. *Mol. Cell Biol.* 32, 648–657

18. Fuekawa, K., Sakano, S., and Teitelbaum, S. L. (2007) Osteoclasts: what do they do and how do they do it? *Am. J. Pathol.* 170, 427–435

19. Dong, Y., Jesse, A. M., Kohn, A., Gunnell, L. M., Honjo, T., Zuscik, M. J., and Teitelbaum, S. L. (2008) NOTCH1 regulates osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblast lineage cells. *J. Biol. Chem.* 283, 6509–6518

20. Fukushima, H., Nakao, A., Okamoto, F., Shin, M., Kajiya, H., Sakano, S., Bigas, A., Jimi, E., and Okabe, K. (2008) The association of Notch2 and NF-κB accelerates RANKL-induced osteogenesis. *Mol. Cell Biol.* 28, 6402–6412

21. Zanotti, S., Smerdel-Ramoya, A., and Canalis, E. (2011) Hey1 and Hey2 signaling in osteoblasts and bone diseases. *Bone* 49, 4692–4705

22. Gazzarino, E., Pereira, R. C., Jorgetti, V., Olson, S., Economides, A. N., and Canalis, E. (2005) Skeletal overexpression of gremlin impairs bone formation and causes osteopenia. *Endocrinology* 146, 655–665

23. Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., and Recker, R. R. (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. *J. Bone Miner. Res.* 2, 595–610

24. McCarthy, T. L., Centrella, M., and Canalis, E. (1990) Cyclic AMP induces insulin-like growth factor I synthesis in osteoblast-enriched cultures. *J. Biol. Chem.* 265, 15353–15356

25. Akazawa, C., Sasai, S., Nakanishi, S., and Kageyama, R. (1992) Molecular characterization of a rat negative regulator with a basic helix-loop-helix structure predominantly expressed in the developing nervous system. *J. Biol. Chem.* 267, 21879–21885

26. Liu, J., Stewart, C., Puchacz, E., Mackowiak, S., Shalhoub, V., Collart, D., Zambetti, G., and Stein, G. (1989) Structure of the rat osteocalcin gene and characterization of a rat negative regulator with a basic helix-loop-helix structure predominantly expressed in the developing nervous system. *J. Biol. Chem.* 267, 21879–21885
47. Sokal, R. R., and Rohlf, F. J. (1981) *Biometry*, 2nd Edition, W. H. Freeman, San Francisco, CA
48. Canalis, E., Parker, K., Feng, J. Q., and Zanotti, S. (2013) Osteoblast lineage-specific effects of notch activation in the skeleton. *Endocrinology* **154**, 623–634
49. Hildebrand, T., and Rüegsegger, P. (1997) Quantification of bone microarchitecture with the Structure Model Index. *Comput. Methods Biomech. Biomed. Engin.* **1**, 15–23
50. Mundy, G. R. (2007) Osteoporosis and inflammation. *Nutr. Rev.* **65**, S147–S151
51. Boban, I., Jacquin, C., Prior, K., Barisic-Dujmovic, T., Maye, P., Clark, S. H., and Aguila, H. L. (2006) The 3.6 kb DNA fragment from the rat Col1a1 gene promoter drives the expression of genes in both osteoblast and osteoclast lineage cells. *Bone* **39**, 1302–1312
52. Scheller, E. L., Leinninger, G. M., Hankenson, K. D., Myers, M. G., Jr., and Krebsbach, P. H. (2011) Ectopic expression of Col2.3 and Col3.6 promoters in the brain and association with leptin signaling. *Cells Tissues Organs* **194**, 268–273
53. Manolagas, S. C., Kousteni, S., and Jilka, R. L. (2002) Sex steroids and bone. *Recent Prog. Horm. Res.* **57**, 385–409
54. O’Brien, C. A., Lin, S. C., Bellido, T., and Manolagas, S. C. (2000) Expression levels of gp130 in bone marrow stromal cells determine the magnitude of osteoclastogenic signals generated by IL-6-type cytokines. *J. Cell Biochem.* **79**, 532–541
55. Yoshitake, F., Itoh, S., Narita, H., Ishihara, K., and Ebisu, S. (2008) Interleukin-6 directly inhibits osteoclast differentiation by suppressing receptor activator of NF-κB signaling pathways. *J. Biol. Chem.* **283**, 11535–11540